Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
|
BridgeBio Pharma, Inc. (BBIO)
|
Add to portfolio |
|
|
|
| Price: |
$16.29
| | Metrics |
| OS: |
162.5
|
M
| |
|
|
| Market cap: |
$2.65
|
B
| |
|
|
|
Net cash:
|
$302
|
M
| |
$1.86
|
per share
|
|
EV:
|
$2.34
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 69.7 | 8.2 | 40.6 | 0.0 | 0.0 |
| Revenue growth | 745.1% | -79.7% | | | |
| Cost of goods sold | 2.7 | 478.0 | 303.2 | 0.0 | 0.0 |
| Gross profit | 67.0 | -469.8 | -262.7 | 0.0 | 0.0 |
| Gross margin | 96.1% | -5694.7% | -647.6% | | |
| Selling, general and administrative | 643.6 | 4.7 | 3.6 | | |
| Research and development | | | | 140.1 | 30.6 |
| General and administrative | | | | 43.6 | 13.3 |
| EBITA | -574.0 | -469.8 | -262.7 | -164.6 | -43.9 |
| EBITA margin | -823.4% | -5694.7% | -647.6% | | |
| Amortization of intangibles | 2.6 | | | | |
| EBIT | -576.6 | -469.8 | -262.7 | -164.6 | -43.9 |
| EBIT margin | -827.1% | -5694.7% | -647.6% | | |
| Pre-tax income | 0.0 | 0.0 | 0.0 | 169.5 | 43.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.0% | 0.0% |
| Net income | 0.0 | 0.0 | 0.0 | -130.7 | -30.6 |
| Net margin | 0.0% | 0.0% | 0.0% | | |
| |
| Diluted EPS | $0.00 | $0.00 | $0.00 | ($2.12) | ($1.00) |
| Shares outstanding (diluted) | 144.4 | 118.0 | 105.1 | 61.8 | 30.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|